Roche Bets Up to $1 Billion to Solve Gene Therapy’s Big Problem

Press

October 24, 2024

Bloomberg

TOC LINK

Press

Published

October 24, 2024

Dyno Therapeutics to Present New Capsids and AI Advancements in Gene Delivery at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Announcements

Dyno Therapeutics

April 27, 2026

Dyno Therapeutics to Present New Capsids and AI Advancements in Gene Delivery at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Announcements

Dyno Therapeutics

April 27, 2026

Dyno Therapeutics Launches Two New AAV Capsids and AI Platform for Rare Disease Therapeutic Development at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Announcements

Dyno Therapeutics

May 13, 2026

Dyno Therapeutics Launches Two New AAV Capsids and AI Platform for Rare Disease Therapeutic Development at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Announcements

Dyno Therapeutics

May 13, 2026

Dyno Therapeutics Announces Expanded Frontiers Network and Second Annual Genetic Agency Technology Conference (GATC)

Announcements

Dyno Therapeutics

May 13, 2026

Dyno Therapeutics Announces Expanded Frontiers Network and Second Annual Genetic Agency Technology Conference (GATC)

Announcements

Dyno Therapeutics

May 13, 2026

Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design

Announcements

Dyno Therapeutics

April 8, 2026

Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design

Announcements

Dyno Therapeutics

April 8, 2026

Roche Bets Up to $1 Billion to Solve Gene Therapy’s Big Problem

More like this

Dyno Therapeutics to Present New Capsids and AI Advancements in Gene Delivery at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Dyno Therapeutics to Present New Capsids and AI Advancements in Gene Delivery at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Dyno Therapeutics Launches Two New AAV Capsids and AI Platform for Rare Disease Therapeutic Development at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Dyno Therapeutics Launches Two New AAV Capsids and AI Platform for Rare Disease Therapeutic Development at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Dyno Therapeutics Announces Expanded Frontiers Network and Second Annual Genetic Agency Technology Conference (GATC)

Dyno Therapeutics Announces Expanded Frontiers Network and Second Annual Genetic Agency Technology Conference (GATC)

Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design

Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design